Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
Recruiting · NCT04467723 · Registry updated 2026-01-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC | Disease Attributes, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-01-28 | NCT04467723 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| parkview cancer institute | 1 |
| University of Kansas Medical Center | 169 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The University of Kansas Cancer Center (KUCC) | Fairway | United States | 4 |
| The University of Kansas Cancer Center, Westwood Campus | Kansas City | United States | 6 |